

# MaxThera, Inc.

**Contact:**

Ania Knap, PhD  
MaxThera, Inc  
978-993-0268  
akknep@maxthera.com

Phil Holberton  
MaxThera, Inc  
978-927-8900  
pholberton@maxthera.com

## **MaxThera Awarded Additional NIH Grant of \$600,000 Will Fund Research for New Antibiotics to Treat Lethal Infections**

**Beverly, Mass., February 1, 2006**—MaxThera today announced it received notice that the National Institute of Allergy and Infectious Diseases awarded a SBIR Phase I grant in the amount of \$600,000 through January 2008.

“I am delighted we have received this favorable peer evaluation of our scientific programs” said Dr Knap, President & CSO of MaxThera, Inc. “Receipt of this grant award, following the \$1.45 BioShield grant awarded in 2005, further supports the premise that our approach to designing new antibiotics that beat resistance is appropriate and is of national importance”, she continued.

The 2-year Phase I grant will provide support to the Company’s ongoing efforts to design and develop new antibiotics to successfully treat potential lethal infections that are complicated by antibiotic resistance. The Company is eligible to submit a Phase II application at the end of the Phase I funding. Phase II program grants provide for up to \$1,000,000 per year for 3 years.

### **About MaxThera, Inc**

MaxThera, Inc. is a start-up biopharmaceutical company engaged in the development of novel drugs to treat bacterial infections, especially those resistant to existing antibiotics. The company acquired the rights to a portfolio of potential products and uniquely characterized, genomically derived targets, including three validated targets that have led to the identification of four novel, proprietary chemical lead series. MaxThera’s strategy to limit resistance emergence is to combine the use of these *new* targets in biosynthetic pathways - essential for bacterial survival -with these *novel* structural classes of compounds. This combination of targets and compounds is designed to reset the antibiotic resistance time clock that increasingly plagues the fight against infectious diseases.

###